Graves Disease Clinical Trial
Official title:
Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease
The purpose of this study is to determine whether a brief course of SSKI (saturated solution of potassium iodide) administered preoperatively provides any benefit in the surgical management of patients undergoing thyroidectomy as definitive management of their Graves Disease.
Status | Completed |
Enrollment | 36 |
Est. completion date | April 2013 |
Est. primary completion date | April 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Adult patients with a clinical diagnosis of Graves Disease - Patients who have selected surgical resection as treatment of their Graves Disease - Prior use of anti thyroid medication so that patient is clinically and biochemically euthyroid Exclusion Criteria: - Patients deemed unfit for surgery by operating surgeon or anesthesist - Patients who are clinically hyperthyroid or have T3 or T4 levels 2X the upper limit of normal |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | UMASS Memorial Health Care | Worcester | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
University of Massachusetts, Worcester |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Blood Loss During Surgery | Blood loss in milliliters during surgery. | up to 162 minutes | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05774535 -
Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
|
||
Completed |
NCT02973802 -
ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy
|
Phase 1 | |
Completed |
NCT02491567 -
DNA Methylation and Autoimmune Thyroid Diseases
|
||
Terminated |
NCT01320813 -
Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy
|
N/A | |
Completed |
NCT00432146 -
Effect of Lugol's Solution in the Patients With Graves' Disease
|
N/A | |
Recruiting |
NCT06081439 -
Validating Immunological Markers Associated With Mental Fatigue in Graves' Disease
|
||
Not yet recruiting |
NCT06327828 -
Methimazole in Graves' Disease - Comparing the Computer-aided Treatment DigiThy Versus Usual Care
|
N/A | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04135573 -
The Relationship Between NK Cell and Graves' Disease
|
||
Recruiting |
NCT06134219 -
Course for Brain Fatigue After Graves' Disease Controlled Study
|
N/A | |
Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
Recruiting |
NCT05678374 -
Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
|
||
Completed |
NCT03009357 -
Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis
|
||
Recruiting |
NCT05510609 -
Three-dimensional Ultrasonography Thyroid Volume Measurement.
|
N/A | |
Not yet recruiting |
NCT06426758 -
Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation
|
||
Recruiting |
NCT05907668 -
A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
|
Phase 2 | |
Recruiting |
NCT06275373 -
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
|
||
Recruiting |
NCT03303053 -
Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism
|
Phase 3 | |
Recruiting |
NCT05461820 -
Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease
|
Phase 4 |